Since IDO1 inhibitors have been proven to reduce Tregs within the tumor microenvironment (25, 26), we explored the potential of combining DSP-0509 with an IDO1 inhibitor to enhance the anti-tumor activity of DSP-0509 while simultaneously reducing Tregs. The gene discussed is IDO1; the disease is neoplasm.